Becton, Dickinson and Company (BD) has introduced a new MX instrument for high-throughput infectious disease testing.

The new BD COR MX as well as its assay for sexually transmitted infections have been CE marked to the IVD directive 98/79/EC.

It is the final piece of the BD COR System that also includes a GX instrument to screen for HPV infections and PX instrument for diagnostic samples preparation.

The MX instrument is based on the BD Max System molecular PCR technology platform, which is a medium-throughput system used in hospital labs.

Th company intends to use the BD Max system menu of infectious disease tests for creating assays which can be used in high-throughput central reference laboratories on the BD COR System.

BD Molecular Diagnostics vice-president Nikos Pavlidis said: “The BD COR PX/GX system is already used at laboratories across Europe and in Israel, helping to improve diagnostics and positively impact patient care.

“The availability of the MX instrument expands the use of the platform and automates testing for an expanding list of high-demand, essential assays for women’s health and STI testing using multiplex PCR assay design, starting with BD’s CTGCTV2 test.”

The BD CTGCTV2 for BD COR System is the first test available on the MX instrument and is designed to detect the three prevalent non-viral sexually transmitted infections such as Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV).

It has also been included on the Australian Register for Therapeutic Goods (ARTG).

The company stated that the MX instrument will perform the BD CTGCTV2 molecular assay’s analytical steps, including detection, amplification, and extraction.

Recently, BD acquired Tissuemed, a self-adhesive surgical sealant films developer, for an undisclosed amount.